https://www.selleckchem.com/pr....oducts/ro-61-8048.ht
Venous (VTEs) and arterial thromboembolic events (ATEs) are causes of morbidity, disability, mortality, and increase in treatment costs in cancer patients. The risk associated with immune checkpoint inhibitors (ICIs) has not yet been clarified. The primary objective of this systematic review was to evaluate the incidence of VTEs and ATEs in patients treated with ICIs as single agents or in combination with other treatments. Data from retrospective and prospective studies were selected from PubMed, EMBASE, SCOPUS, and The Cochrane Lib
Like
Comment
Share
